Aryeh Keehn1, Ethan Ludmir1, Jacob Taylor1, Farhang Rabbani2. 1. Department of Urology, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, 10461, USA. 2. Urology Division, Department of Surgery, Cancer Treatment Centers of America - Southeastern Regional Medical Center, 600 Celebrate Life Parkway, Newnan, GA, 30265, USA. farhang.rabbani@ctca-hope.com.
Abstract
OBJECTIVES: To evaluate the risk of BlCa developing after radiation for PCa, stratified by ethnicity and follow-up duration. METHODS: The 1973-2011 surveillance, epidemiology and end results database was used to determine the observed and expected number of BlCa after PCa radiation. The adjusted relative risks (RRs) of developing BlCa were calculated for the various radiation modalities relative to no radiation, stratified by ethnicity and follow-up duration. BlCa characteristics were compared between patients with a history of prostate radiation and those without PCa. RESULTS: PCa was radiated in 346,429 men, 6401 of whom developed BlCa versus 2464 expected cases [SIR (95 % CI) of 2.60 (2.53-2.66)]. All radiation modalities were found to have an increased RR of developing BlCa after 10 years, with brachytherapy having a significantly higher RR than external beam radiation (EBRT) or combined EBRT and brachytherapy in Caucasian men and a significantly higher RR than EBRT in men of other/unknown ethnicity. Post-radiation BlCa, in particular that after brachytherapy, had higher grade (P = 0.0001) and lower stage (P = 0.0001) versus the general population. CONCLUSIONS: The increased risk of BlCa after prostate radiation occurs predominantly after 10 years, regardless of ethnicity. The RR of developing BlCa after 10 years is significantly higher following brachytherapy than after EBRT or EBRT and brachytherapy. Bladder cancers after prostate radiation, especially after brachytherapy, are generally lower stage but higher grade than those in patients without PCa.
OBJECTIVES: To evaluate the risk of BlCa developing after radiation for PCa, stratified by ethnicity and follow-up duration. METHODS: The 1973-2011 surveillance, epidemiology and end results database was used to determine the observed and expected number of BlCa after PCa radiation. The adjusted relative risks (RRs) of developing BlCa were calculated for the various radiation modalities relative to no radiation, stratified by ethnicity and follow-up duration. BlCa characteristics were compared between patients with a history of prostate radiation and those without PCa. RESULTS: PCa was radiated in 346,429 men, 6401 of whom developed BlCa versus 2464 expected cases [SIR (95 % CI) of 2.60 (2.53-2.66)]. All radiation modalities were found to have an increased RR of developing BlCa after 10 years, with brachytherapy having a significantly higher RR than external beam radiation (EBRT) or combined EBRT and brachytherapy in Caucasian men and a significantly higher RR than EBRT in men of other/unknown ethnicity. Post-radiation BlCa, in particular that after brachytherapy, had higher grade (P = 0.0001) and lower stage (P = 0.0001) versus the general population. CONCLUSIONS: The increased risk of BlCa after prostate radiation occurs predominantly after 10 years, regardless of ethnicity. The RR of developing BlCa after 10 years is significantly higher following brachytherapy than after EBRT or EBRT and brachytherapy. Bladder cancers after prostate radiation, especially after brachytherapy, are generally lower stage but higher grade than those in patients without PCa.
Entities:
Keywords:
Brachytherapy/adverse effects; Neoplasms/radiotherapy; Prostatic; Radiation-induced/epidemiology; SEER program; Second primary/epidemiology
Authors: David S Yee; Shahrokh F Shariat; William T Lowrance; Joseph R Sterbis; Kinjal C Vora; Bernard H Bochner; S Machele Donat; Harry W Herr; Guido Dalbagni; Jaspreet S Sandhu Journal: J Urol Date: 2010-03-17 Impact factor: 7.450
Authors: H Musunuru; M Mason; L Murray; B Al-Qaisieh; P Bownes; J Smith; K Franks; B Carey; D Bottomley; A M Henry Journal: Clin Oncol (R Coll Radiol) Date: 2014-02-06 Impact factor: 4.126
Authors: Anurag K Singh; Terry L Mashtare; Susan A McCloskey; Stefanie A Seixas-Mikelus; Hyung L Kim; Kilian Salerno May Journal: Int J Radiat Oncol Biol Phys Date: 2010-03-28 Impact factor: 7.038
Authors: Stanley L Liauw; John E Sylvester; Christopher G Morris; John C Blasko; Peter D Grimm Journal: Int J Radiat Oncol Biol Phys Date: 2006-08-02 Impact factor: 7.038
Authors: Amar Singh; Yoshihisa Kinoshita; Peter M Rovito; Steve Landas; Jon Silberstein; Imad Nsouli; Ching Y Wang; Gabriel P Haas Journal: J Urol Date: 2005-05 Impact factor: 7.450
Authors: Stephen Boorjian; Janet E Cowan; Badrinath R Konety; Janeen DuChane; Ashutosh Tewari; Peter R Carroll; Christopher J Kane Journal: J Urol Date: 2007-03 Impact factor: 7.450
Authors: Matthew Mossanen; Filipe L F Carvalho; Vinayak Muralidhar; Mark A Preston; Brendan Reardon; Jake R Conway; Catherine Curran; Dory Freeman; Sybil Sha; Guru Sonpavde; Michelle Hirsch; Adam S Kibel; Eliezer M Van Allen; Kent W Mouw Journal: Eur Urol Date: 2021-12-23 Impact factor: 24.267
Authors: Marie-Christina Jahreiß; Katja K H Aben; Mischa S Hoogeman; Maarten L P Dirkx; Kim C de Vries; Luca Incrocci; Wilma D Heemsbergen Journal: Front Oncol Date: 2020-11-13 Impact factor: 6.244
Authors: Marie-Christina Jahreiß; Wilma D Heemsbergen; Bo van Santvoort; Mischa Hoogeman; Maarten Dirkx; Floris J Pos; Tomas Janssen; Andre Dekker; Ben Vanneste; Andre Minken; Carel Hoekstra; Robert J Smeenk; Inge M van Oort; Chris H Bangma; Luca Incrocci; Katja K H Aben Journal: Front Oncol Date: 2021-11-26 Impact factor: 6.244